دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Association of Novel Locus With Rheumatic Heart Disease in Black African Individuals: Findings From the RHDGen Study
Tafadzwa Machipisa, MPhil1,2,3,4,5; Michael Chong, MSc3,4,5; Babu Muhamed, PhD1,2,3,4,5; Chishala Chishala, MD, MMed1,2; Gasnat Shaboodien, PhD1,2; Shahiemah Pandie, BCom1; Jantina de Vries, DPhil1; Nakita Laing, MSc1; Alexia Joachim, RN1; Rezeen Daniels, NHCert(Manage)1; Mpiko Ntsekhe, MD, PhD1; Christopher T. Hugo-Hamman, MD, MMed6; Bernard Gitura, MD, MMed7; Stephen Ogendo, MD, MMed7; Peter Lwabi, MD, MMed8; Emmy Okello, PhD8; Albertino Damasceno, MD, PhD9; Celia Novela, RN9; Ana O. Mocumbi, MD, PhD10; Goeffrey Madeira, MD11; John Musuku, MD, MMed12; Agnes Mtaja, MD, MMed12; Ahmed ElSayed, MD13; Huda H. M. Elhassan, MD13; Fidelia Bode-Thomas, MD14; Basil N. Okeahialam, MD14; Liesl J. Zühlke, MD, PhD1,15; Nicola Mulder, PhD16; Raj Ramesar, PhD17; Maia Lesosky, PhD1; Tom Parks, MD18; Heather J. Cordell, DPhil19; Bernard Keavney, BM, BCh, DM20,21; Mark E. Engel, MPH, PhD1; Guillaume Paré, MD, MSc3,4,5,22
doi : 10.1001/jamacardio.2021.1627
JAMA Cardiol. 2021;6(9):1000-1011
Rheumatic heart disease (RHD), a sequela of rheumatic fever characterized by permanent heart valve damage, is the leading cause of cardiac surgery in Africa. However, its pathophysiologic characteristics and genetics are poorly understood. Understanding genetic susceptibility may aid in prevention, control, and interventions to eliminate RHD.
Genetic Variants Associated With Unexplained Sudden Cardiac Death in Adult White and African American Individuals
Liang Guo, PhD1,2; Sho Torii, MD, PhD1,3; Raquel Fernandez, BS1; Ryan E. Braumann, BS1; Daniela T. Fuller, BS1; Ka-Hyun Paek, BS1; Neel V. Gadhoke, BS1; Kristin A. Maloney, MS, MGC4; Kathryn Harris, MD4; Christina M. Mayhew, BS1; Roya Zarpak, MD, MS1; Laura M. Stevens, PhD5; Brady J. Gaynor, MS4; Hiroyuki Jinnouchi, MD, PhD1; Atsushi Sakamoto, MD, PhD1; Yu Sato, MD1; Hiroyoshi Mori, MD, PhD1,6; Matthew D. Kutyna, MS1; Parker J. Lee, BS1,4; Leah M. Weinstein, BS1; Carlos J. Collado-Rivera, MD1; Bakr B. Ali, BS1; Dheeraj R. Atmakuri, BS1; Roma Dhingra1; Emma L. B. Finn1; Mack W. Bell, MD1,4; Megan Lynch, BS4; Anne Cornelissen, MD1; Salome H. Kuntz, MD1; Joo-Hyung Park, MD1; Robert Kutys, MS1; Ji-Eun Park, MD4; Libin Wang, MD, PhD4; Susie N. Hong, MD, MSc4; Anuj Gupta, MD4; Jennifer L. Hall, PhD5; Frank D. Kolodgie, PhD1; Maria E. Romero, MD1; Linda J. B. Jeng, MD, PhD7; Braxton D. Mitchell, PhD, MPH4; Dipti Surve, MD1; David R. Fowler, MD8; Charles C. Hong, MD, PhD4; Renu Virmani, MD1; Aloke V. Finn, MD1,4
doi : 10.1001/jamacardio.2021.1573
JAMA Cardiol. 2021;6(9):1013-1022
Unexplained sudden cardiac death (SCD) describes SCD with no cause identified. Genetic testing helps to diagnose inherited cardiac diseases in unexplained SCD; however, the associations between pathogenic or likely pathogenic (P/LP) variants of inherited cardiomyopathies (CMs) and arrhythmia syndromes and the risk of unexplained SCD in both White and African American adults living the United States has never been systematically examined.
Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial
Harvey D. White, DSc1; Sean M. O’Brien, PhD2; Karen P. Alexander, MD2; William E. Boden, MD3; Sripal Bangalore, MD, MHA4; Jianghao Li, PhD2; Cholenahally N. Manjunath, MD5; Jose Luis Lopez-Sendon, MD6; Jesus Peteiro, MD7; Gilbert Gosselin, MD8; Jeffrey S. Berger, MD, MS4; Aldo Pietro Maggioni, MD9; Harmony R. Reynolds, MD4; Judith S. Hochman, MD4; David J. Maron, MD10
doi : 10.1001/jamacardio.2021.1651
JAMA Cardiol. 2021;6(9):1023-1031
Traditional time-to-event analyses rate events occurring early as more important than later events, even if later events are more severe, eg, death. Days alive out of hospital (DAOH) adds a patient-focused perspective beyond trial end points.
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial
Birgit Vogel, MD1; Usman Baber, MD, MS1,2; David J. Cohen, MD, MSc3,4; Samantha Sartori, PhD1; Samin K. Sharma, MD1; Dominick J. Angiolillo, MD, PhD5; Serdar Farhan, MD1; Ridhima Goel, MD1; Zhongjie Zhang, MPH1; Carlo Briguori, MD, PhD6; Timothy Collier, MSc7; George Dangas, MD, PhD1; Dariusz Dudek, MD, PhD8,9; Javier Escaned, MD, PhD10; Robert Gil, MD, PhD11; Ya-ling Han, MD, PhD12; Upendra Kaul, MD13; Ran Kornowski, MD14; Mitchell W. Krucoff, MD15; Vijay Kunadian, MBBS, MD16; Shamir R. Mehta, MD, MSc17; David Moliterno, MD18; E. Magnus Ohman, MD15; Gennaro Sardella, MD19; Bernhard Witzenbichler, MD20; C. Michael Gibson, MD, MS21; Stuart Pocock, PhD7; Kurt Huber, MD22,23; Roxana Mehran, MD1
doi : 10.1001/jamacardio.2021.1720
JAMA Cardiol. 2021;6(9):1032-1041
Shortened dual antiplatelet therapy followed by potent P2Y12 receptor inhibitor monotherapy reduces bleeding without increasing ischemic events after percutaneous coronary intervention (PCI).
Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery: A Post Hoc Analysis From the COMPASS Trial
André Lamy, MD1,2,3; Austin Browne, PhD1; Tej Sheth, MD1,4; Zhe Zheng, MD5; François Dagenais, MD6; Nicolas Noiseux, MD7; Xin Chen, MD8; Faisal G. Bakaeen, MD9; Miroslav Brtko, MD10; Louis-Mathieu Stevens, MD7; Mariam Alboom, MD2; Shun Fu Lee, PhD1,3; Ingrid Copland1; Yusuf Salim, DPhil1,3,4; John Eikelboom, MBBS1,4; for the COMPASS Investigators
doi : 10.1001/jamacardio.2021.1686
JAMA Cardiol. 2021;6(9):1042-1049
The relative safety and patency of skeletonized vs pedicled internal mammary artery grafts in patients undergoing coronary artery bypass graft (CABG) surgery are unknown.
Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A Prespecified Secondary Analysis of a Randomized Clinical Trial
G. Greg Peterson, PhD, MPA1; Jia Pu, PhD, MA2; David J. Magid, MD, MPH3; Linda Barterian, MPP, MPH4; Keith Kranker, PhD5; Michael Barna, MA4; Leslie Conwell, PhD, MHS1; Adam Rose, MD, MSc6; Laura Blue, PhD, MA1; Amanda Markovitz, ScD, MPH7; Nancy McCall, ScD, SM1; Patricia Markovich, PhD8
doi : 10.1001/jamacardio.2021.1565
JAMA Cardiol. 2021;6(9):1050-1059
The Million Hearts Cardiovascular Disease (CVD) Risk Reduction Model pays provider organizations for measuring and reducing Medicare patients’ cardiovascular risk.
Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US
Christopher P. Cannon, MD1,2; James A. de Lemos, MD3; Robert S. Rosenson, MD4; Christie M. Ballantyne, MD5,10; Yuyin Liu, PhD, MS2; Qi Gao, MS2; Tamara Palagashvilli, PharmD6; Shushama Alam, PharmD6; Katherine E. Mues, PhD, MPH6; Deepak L. Bhatt, MD, MPH7; Mikhail N. Kosiborod, MD8,9; for the GOULD Investigators
doi : 10.1001/jamacardio.2021.1810
JAMA Cardiol. 2021;6(9):1060-1068
Guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) recommend intensive statin therapy and adding nonstatin therapy if low-density lipoprotein cholesterol (LDL-C) levels are 70 mg/dL or more. Compliance with guidelines is often low.
Association of Diet Quality With Prevalence of Clonal Hematopoiesis and Adverse Cardiovascular Events
Romit Bhattacharya, MD1,2,3; Seyedeh Maryam Zekavat, BS2,4,5; Md Mesbah Uddin, PhD2,4; James Pirruccello, MD1,2,3; Abhishek Niroula, PhD2,6; Christopher Gibson, MD6; Gabriel K. Griffin, MD7,8; Peter Libby, MD9; Benjamin L. Ebert, MD, PhD9; Alexander Bick, MD, PhD10; Pradeep Natarajan, MD, MMSc1,2,3
doi : 10.1001/jamacardio.2021.1678
JAMA Cardiol. 2021;6(9):1069-1077
Clonal hematopoiesis of indeterminate potential (CHIP), the expansion of somatic leukemogenic variations in hematopoietic stem cells, has been associated with atherosclerotic cardiovascular disease. Because the inherited risk of developing CHIP is low, lifestyle elements such as dietary factors may be associated with the development and outcomes of CHIP.
Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry
Curt J. Daniels, MD1; Saurabh Rajpal, MBBS, MD1; Joel T. Greenshields, MS2; Geoffrey L. Rosenthal, MD3; Eugene H. Chung, MD4; Michael Terrin, MD3; Jean Jeudy, MD3; Scott E. Mattson, DO5; Ian H. Law, MD6; James Borchers, MD7; Richard Kovacs, MD8; Jeffrey Kovan, DO9; Sami F. Rifat, MD4; Jennifer Albrecht, PhD3; Ana I. Bento, PhD2; Lonnie Albers, MD10; David Bernhardt, MD11; Carly Day, MD12; Suzanne Hecht, MD13; Andrew Hipskind, MD14; Jeffrey Mjaanes, MD15; David Olson, MD13; Yvette L. Rooks, MD16; Emily C. Somers, PhD4; Matthew S. Tong, DO1; Jeffrey Wisinski, DO17; Jason Womack, MD18; Carrie Esopenko, PhD19; Christopher J. Kratochvil, MD20; Lawrence D. Rink, MD5; for the Big Ten COVID-19 Cardiac Registry Investigators
doi : 10.1001/jamacardio.2021.2065
JAMA Cardiol. 2021;6(9):1078-1087
Myocarditis is a leading cause of sudden death in competitive athletes. Myocardial inflammation is known to occur with SARS-CoV-2. Different screening approaches for detection of myocarditis have been reported. The Big Ten Conference requires comprehensive cardiac testing including cardiac magnetic resonance (CMR) imaging for all athletes with COVID-19, allowing comparison of screening approaches.
Trade-off Between Bleeding and Thrombotic Risk in Patients With Academic Research Consortium for High Bleeding Risk
Hironori Hara, MD1; Masafumi Ono, MD1; Hideyuki Kawashima, MD1; Yoshinobu Onuma, MD, PhD1; Patrick W. Serruys, MD, PhD1
doi : 10.1001/jamacardio.2021.1558
JAMA Cardiol. 2021;6(9):1092-1094
Differences in Administrative Claims Data for Coronary Artery Bypass Grafting Between International Classification of Diseases, Ninth Revision and Tenth Revision Coding
Justin M. Schaffer, MD1; John J. Squiers, MD2; Jasjit K. Banwait, PhD2; Sarah Hale, CCRC2; William H. Ryan, MD1; Michael J. Mack, MD1,2; J. Michael DiMaio, MD1
doi : 10.1001/jamacardio.2021.1595
JAMA Cardiol. 2021;6(9):1094-1096
Prevention and Mitigation of Heart Failure in the Treatment of Calcific Aortic Stenosis: A Unifying Therapeutic Principle
Brian R. Lindman, MD, MSc1,2; JoAnn Lindenfeld, MD1
doi : 10.1001/jamacardio.2021.2082
JAMA Cardiol. 2021;6(9):993-994
Return to Play for Athletes After COVID-19 Infection: The Fog Begins to Clear
James E. Udelson, MD1; Ethan J. Rowin, MD1; Barry J. Maron, MD1
doi : 10.1001/jamacardio.2021.2079
JAMA Cardiol. 2021;6(9):997-999
Troubleshooting CardioMEMS After Implant—Failure to Read
Ersilia M. DeFilippis, MD1; Ajay J. Kirtane, MD, SM2; Kelly Axsom, MD1,3
doi : 10.1001/jamacardio.2021.1820
JAMA Cardiol. 2021;6(9):1090-1091
Guideline Update on Indications for Transcatheter Aortic Valve Implantation Based on the 2020 American College of Cardiology/American Heart Association Guidelines for Management of Valvular Heart Disease
Thoralf M. Sundt, MD1; Hani Jneid, MD2
doi : 10.1001/jamacardio.2021.2534
JAMA Cardiol. 2021;6(9):1088-1089
A Woman With a Right Atrial Mass
Seyed Hossein Aalaei-Andabili, MD1; Libin Wang, MD, PhD1; Diljon Chahal, MD1
doi : 10.1001/jamacardio.2021.2609
JAMA Cardiol. 2021;6(9):e212609
Clinical Utility of Lipoprotein(a) for Screening Does Not Determine Clinical Utility of Lipoprotein(a) for the Patient
Christian Gerald Schrock, MD1
doi : 10.1001/jamacardio.2021.1592
JAMA Cardiol. 2021;6(9):1096-1097
Clinical Utility of Lipoprotein(a) for Screening Does Not Determine Clinical Utility of Lipoprotein(a) for the Patient—Reply
Mark Trinder, MSc1,2; Pradeep Natarajan, MD, MMSc2,3,4,5
doi : 10.1001/jamacardio.2021.1589
JAMA Cardiol. 2021;6(9):1097
A Still-Ignored Cardiovascular Risk Factor—A History of Preeclampsia
Edoardo Sciatti, MD1; Rossana Orabona, MD2
doi : 10.1001/jamacardio.2021.1958
JAMA Cardiol. 2021;6(9):1097-1098
A Still-Ignored Cardiovascular Risk Factor—A History of Preeclampsia—Reply
Sagar B. Dugani, MD, PhD1,2; M. Vinayaga Moorthy, PhD1,3; Samia Mora, MD, MHS1,3,4
doi : 10.1001/jamacardio.2021.1961
JAMA Cardiol. 2021;6(9):1098
Expanding Discovery in Cardiovascular Genome-Wide Association Studies
Pradeep Natarajan, MD, MMSc1,2,3,4; Elizabeth M. McNally, MD, PhD5,6,7
doi : 10.1001/jamacardio.2021.1635
JAMA Cardiol. 2021;6(9):1012
